WuXi Biologics (Cayman) Inc.
$6.22-3.5%1Y+41.5%
Mentions · last 7 days
0
Price updated 1h ago·X counts updated 4h ago
What it does
Plain-English summary of the business — what they sell and how they make money.
Industry overviewAI analysisGenerated by AI from underlying data
Where Biotechnology sits in its cycle right now — and what that implies for $WXIBF.
Biotechnology
GLP-1 oral formulation competition — emerging clinical data from pipeline challengers — is the central bifurcation: platform holders (LLY, NVO) defend on efficacy breadth while precision oncology names decouple entirely. FDA catalyst cadence over the next 60 days sets the near-term tone.
What this means for $WXIBF
Partial — branded pharmaceutical revenue is exposed to patent cliff dynamics and GLP-1 category cannibalization; WuXi Biologics (Cayman) Inc.
Top industry ETF
$IBBiShares Biotechnology ETF
+12.1%YTD
+50.1%1Y
Fundamentals & catalyst
Profitability, valuation, and the next earnings event — at a glance, with rule-of-thumb signals.
Key ratios
P/E
37.6How much investors are paying per dollar of profit the company actually earned in the last 12 months. Lower means the stock looks cheaper relative to earnings.~15–25 is typical for the S&P 500; high-growth names trade 30+; hyper-growth or speculative can be 100+ or negative.ROIC
9.3%What percentage return the business earns on every dollar of capital (equity + debt) deployed in operations. The cleanest measure of business quality.Above ~15% is high-quality; consistently above 25% suggests a real moat. Below the company's cost of capital is value-destroying.Op margin
30.5%Operating profit (after sales, marketing, R&D, and overhead but before interest and taxes) as a percentage of revenue. The clearest view of how well the underlying business is run.Mature business above 20% is healthy; software businesses can run 30%+; commodity / retail businesses operate in single digits.FCF yield
1.5%Free cash flow (operating cash flow minus capex) divided by the company's market cap. The cash-on-cash return you'd get owning the whole business at today's price.Above ~5% is attractive; below ~2% means you're paying up for growth. Capital-light businesses (software) run higher than capital-heavy ones (utilities).P/S
8.5Same idea as P/E but per dollar of revenue. Useful for companies that aren't profitable yet, where P/E is meaningless.Under ~2 is cheap; software / SaaS often runs 8–15; well above 20 implies the market is pricing in very high future growth.ROE
10.6%Net income as a percentage of shareholders' equity. Similar to ROIC but counts only the equity side.Above 20% is strong, but can be inflated by leverage — a heavily indebted company can show high ROE with weak underlying ROIC.Gross margin
46.0%Revenue minus the direct cost of producing what was sold, as a percentage of revenue. The first read on whether the product is structurally profitable.Software / SaaS is typically 70%+; consumer goods 30–50%; commodity / hardware businesses can be under 20%.D/E
0.1Total debt divided by shareholders' equity. Measures how much the business runs on borrowed money versus owner capital.Under 1 is conservative; 1–2 is typical for mature businesses; over 2 is leveraged and more sensitive to interest rates.Past earnings
QuarterReportedActualEstimateSurprise
Q2 2026Aug 25, 2026$0.09$0.07+28.9%
Q4 2025Mar 24, 2026$0.09$0.090.0%
Q2 2025Aug 19, 2025$0.08$0.06+24.1%
Q4 2024Mar 25, 2025$0.03$0.06-48.9%
Next earningsTue, Mar 23·consensus EPS $0.11
Quarterly trend
QuarterRevenueYoYGrossOpEPSFCF
Q4 FY25$11.6B+36.3%48.7%33.1%$0.63$2.8B
Q2 FY25$10.0B+17.2%42.7%27.4%$0.55$-93.7M
Q4 FY24$10.1B+25.3%42.6%31.2%$0.46$1.9B
Q2 FY24$8.6B+19.0%39.1%21.2%$0.35$-565.3M
Forward consensus
FYRevenueRangeEPSRangeAnalysts
FY26$26.2B$25.9B – $27.5B$1.31$1.26 – $1.4623
FY27$31.0B$29.7B – $34.8B$1.65$1.59 – $1.8323
FY28$36.7B$35.6B – $39.9B$2.01$1.93 – $2.2313
FY29$42.4B$41.1B – $46.0B$2.68$2.58 – $2.9911
FY30$46.3B$44.9B – $50.3B$2.84$2.73 – $3.1511
Setup & momentum
Volume, range, and moving-average position — the technical setup driving short-term moves.
Right now
Vol vs 30dToday's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.—Today's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.
52w rangeWhere the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.91%Where the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.
vs 50d MALatest close vs the 50-day simple moving average. Positive = short-term trend is up.+25.6%Latest close vs the 50-day simple moving average. Positive = short-term trend is up.
vs 200d MALatest close vs the 200-day simple moving average. Positive = long-term trend is up.+36.1%Latest close vs the 200-day simple moving average. Positive = long-term trend is up.
Float & profile
FloatMega float · 3.7B shFree-float shares — the slice of issued stock actually available to trade. Lower buckets squeeze harder on a catalyst.Traded today0.0% of floatToday's volume as a percent of the free float. Above 5% on a single day is unusually high turnover for the available share count.β0.605-year weekly beta vs the S&P 500. Above 1.5 means the stock typically moves more than the index; below 0.8 moves less.ListedOTCListed on an over-the-counter market (PNK / OTCQB / OTCQX), not a major exchange. Lower disclosure requirements and thinner liquidity.
More in Biotechnology
Peers in the same group — one click to compare setups, fundamentals, and chatter.
Voices on X · last 7 days
No standout posts about $WXIBF on X in the last 7 days.